Search Results
Your search for ,New matches 16919 pages
Showing 2001 - 2050Addition of Lapatinib to Chemoradiotherapy in Non–HPV-Related Head and Neck Cancer
In a phase II trial (RTOG 3501, TRYHARD) reported in JAMA Oncology, Wong et al found that the addition of lapatinib to chemoradiotherapy with cisplatin did not appear to improve progression-free survival in front-line therapy for stage III to IV non–human papillomavirus (HPV)-related head and neck...
New Poll Weighs Necessity of Life Expectancy in Cancer Screening Guidelines
A majority of older adults may disagree with the idea of using life expectancy as part of cancer screening guidelines, according to a new University of Michigan National Poll on Healthy Aging. Background The response goes against a trend in guidelines aimed at helping health-care providers decide...
Diabetes May Be Linked to Lower Survival Among Patients With Multiple Myeloma; Survival Outcomes May Be Race-Dependent
Patients with multiple myeloma who also have diabetes may experience worse overall survival outcomes compared with patients who don’t have diabetes, according to a recent study published by Shah et al in Blood Advances. The new findings demonstrated that the differences in survival may be dependent ...
Liquid Biopsy May Help Identify Patients With NSCLC Who Could Benefit From Radiation Therapy
Liquid biopsy may help determine which patients with oligometastatic non–small cell lung cancer (NSCLC) with metastases may be most likely to benefit from targeted, high-dose radiation therapy rather than drug-based therapy, according to findings simultaneously published by Semenkovich et al in npj ...
Racial and Ethnic Minority Patients With Breast Cancer May Be Less Likely to Receive Palliative Care Than White Patients
Despite a steady increase in palliative care utilization from 2004 to 2020, racial and ethnic minority patients with metastatic breast cancer may be less likely to receive palliative care compared with non-Hispanic White patients with the disease, according to new findings presented by Freeman et...
Using Recent Diagnostic Scans May Cut Time to Treatment for Patients Needing Urgent Palliative Radiotherapy
Using previously taken diagnostic computed tomography (CT) scans in place of CT simulation scans to plan simple palliative radiation treatments may substantially reduce the time spent waiting for urgent treatment, improving the patient experience, a new study suggests. Patients who may benefit from ...
Sexual Activity and Vaginal Dilation Associated With Fewer Side Effects After Chemoradiation for Cervical Cancer
People who engage in sexual activity or vaginal dilation after chemoradiation for cervical cancer are at lower risk for long-term side effects, according to a new study from researchers in Austria. Findings of the EMBRACE study were presented by Kirchheiner et al at the 2023 American Society for...
The New Era of Perioperative Therapy in Non–Small Cell Lung Cancer
Recent developments in surgery and therapeutics are changing the perioperative approach to non–small cell lung cancer (NSCLC). These advances were discussed at the 2023 Debates and Didactics in Hematology and Oncology conference, sponsored by Emory University, by Jennifer W. Carlisle, MD, Assistant ...
Hypofractionated Radiotherapy May Reduce Burden of Head and Neck Cancer in Low- and Middle-Income Countries
Fewer and higher doses of radiation may be effective at treating patients with head and neck squamous cell carcinoma, according to new findings presented by Bentzen et al at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract LBA 02). Background Head and neck squamous...
Liquid Biopsies May Be Predictive of Cancer Recurrence Following Chemoradiation in Patients With Cervical Cancer
Two liquid biopsy tests designed to detect the human papillomavirus (HPV) in the blood may accurately identify patients at high risk of cervical cancer recurrence following the completion of chemoradiation, according to new findings presented by Han et al at the 2023 American Society for Radiation...
Precision Medicine Navigators May Increase Genomic Testing Rates Among Black Patients With Prostate Cancer
The presence of precision medicine navigators may increase the likelihood that patients with prostate cancer, especially Black patients, will receive genomic testing that may help predict the severity of their disease and guide treatment, according to findings presented by Allen et al at the 2023...
Stereotactic Radiotherapy for Patients With Primary RCC Unsuitable for Surgery: FASTRACK II
Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted, high-dose radiation, a new study from Australian and Dutch researchers suggests. A multi-institutional phase II study—TransTasman Radiation Oncology Group (TROG) FASTRACK II—found 100% local...
SBRT vs Standard Radiotherapy for Localized Prostate Cancer: 5-Year Analysis of PACE B
People with intermediate-risk, localized prostate cancer may be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, a new phase III randomized trial suggested. The findings, which...
FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types
On September 29, the U.S. Food and Drug Administration (FDA) granted de novo marketing authorization for the Invitae Common Hereditary Cancers Panel, an in vitro diagnostic test that may help detect hundreds of genetic variants associated with an elevated risk of developing certain cancers. The...
Long-Term Low-Grade Intestinal Inflammation May Be Prevalent Among Patients Who Have Undergone Radiotherapy
Researchers have found that low-grade intestinal inflammation may be a side effect of radiotherapy, according to a recent study published by Devarakonda et al in eBioMedicine. Background Radiotherapy is often necessary to cure cancer or slow down cancer development. Although today’s radiotherapies...
Neoadjuvant Immune Checkpoint Blockade May Be Effective Across Multiple Cancer Types
Neoadjuvant immunotherapy may be effective prior to surgery in multiple types of cancers, according to a recent study published by Topalian et al in Cancer Cell. Background Neoadjuvant immune checkpoint blockades have been a rapidly growing area of research and are currently being tested across...
The Future Priorities of the National Cancer Institute
Fifty-two years ago, President Richard Nixon signed the National Cancer Act of 1971 into law, which established the National Cancer Institute (NCI) in its current form. At the time, the budget was $1.6 billion. Today, it is $7.8 billion, $4.5 billion less than the amount needed to keep up with...
Unconscious Gender Biases and Discrimination Lead to Suboptimal Care for Women
Gender inequalities and discrimination may adversely impact women’s rights and opportunities to avoid cancer risk factors and impede their ability to seek and obtain timely diagnoses and quality cancer care, according to The Lancet Commission on Women, Power, and Cancer published by Ginsburg et al...
Using Whole-Body Imaging Agent to Predict Response to Treatment in HER2-Positive Metastatic Breast Cancer
The novel imaging agent gallium (Ga)-68–ABY-025 may help to predict early metabolic response to HER2-targeted treatment in patients with HER2-positive metastatic breast cancer, according to a recent study published by Alhuseinalkhudhur et al in The Journal of Nuclear Medicine. These findings...
Hyperglycemia Among Patients With Breast Cancer Receiving Alpelisib
Researchers have uncovered elevated rates of hyperglycemia among patients who have breast cancer receiving treatment with alpelisib, according to a recent study published by Shen et al in Cancer. Background Alpelisib is designed to target the phosphoinositide 3-kinase (PI3K) protein, which is...
Does Colon Tumor Location Play a Role in Metastasis and Survival?
There have been demonstrated differences in tumor cell metabolism between right-sided and left-sided colorectal tumors, which could explain the differences observed in their clinical behavior, especially in metastatic disease. Now, new research has found that patients with right-sided colorectal...
First-Line Dabrafenib/Trametinib in Pediatric BRAF V600–Mutated Low-Grade Glioma
In a phase II trial reported in The New England Journal of Medicine, Eric Bouffet, MD, and colleagues found that the combination of dabrafenib and trametinib produced a higher objective response rate vs standard chemotherapy in the first-line treatment of pediatric patients with low-grade glioma...
Mutations in 11 Genes May Be Associated With Aggressive Prostate Cancer
Researchers have singled out mutations in 11 genes associated with aggressive types of prostate cancer, according to a novel study published by Darst et al in JAMA Oncology. The new findings may lead to improvements in diagnosis and treatment. Background Currently, oncologists use genetic tests to...
Bariatric Surgery May Reduce the Risk of Hematologic Malignancies, Particularly Among Female Patients
The risk of developing hematologic malignancies may decrease following bariatric surgery in patients with overweight or obesity, according to a recent study published by Sjöholm et al in The Lancet Healthy Longevity. Background Previous studies have shown that overweight and obesity may be risk...
Carfilzomib and Lenalidomide–Based Therapy in Primary Plasma Cell Leukemia
In a European phase II trial (EMN12/HOVON-129) reported in The Lancet Oncology, van de Donk et al found that the incorporation of carfilzomib and lenalidomide into induction, consolidation, and maintenance therapies was associated with good outcomes in both younger and older patients with primary...
Annual Report to the Nation on the Status of Cancer, Part 2, Focuses on COVID-19’s Impact on Cancer Diagnoses
The Annual Report to the Nation on the Status of Cancer, Part 2—published by Negoita et al in the journal Cancer—showed that new diagnoses of six major cancer types in the United States fell sharply between March and May of 2020, coinciding with the beginning of the COVID-19 pandemic. The six...
FDA Approves Bosutinib for Pediatric Patients With Chronic Myelogenous Leukemia
On September 26, the U.S. Food and Drug Administration (FDA) approved bosutinib (Bosulif) for pediatric patients aged 1 year and older with chronic-phase, Philadelphia chromosome–positive chronic myelogenous leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. The FDA ...
Gynecologic Cancer Misinformation May Be Widespread on TikTok
The majority of information related to gynecologic cancers on the social media platform TikTok may be misleading or inaccurate, according to a recent study published by Morton et al in Gynecologic Oncology. Background “The intent of this study was to understand the needs of patients that may go...
Oral Health May Be Linked to Survival in Patients With Head and Neck Squamous Cell Carcinoma
Investigators have revealed that oral health may be associated with survival in patients with head and neck squamous cell carcinoma, according to a novel study published by Tasoulas et al in the Journal of the National Cancer Institute. Background While survival has improved during the past decades ...
High-Intensity Training May Reduce the Risk of Colorectal Cancer in Patients With Lynch Syndrome
Regular and intense aerobic exercise may be effective at reducing the risk of colorectal cancer in patients with Lynch syndrome by improving the immune system's ability to detect and remove potentially harmful cells, according to a novel study published by Deng et al in Clinical Cancer Research....
Exposure to PFAS and Phenols May Be Linked to Cancer Risk
Investigators have discovered that significantly higher levels of endocrine-disrupting chemicals such as per- and poly-fluoroalkyl substances (PFAS) and phenols may be present in patients with breast, ovarian, skin, and endometrial cancers, according to a recent study published by Cathey et al in...
MD Anderson and Ochsner Health Partner to Create First Fully Integrated Cancer Program in Louisiana
The University of Texas MD Anderson Cancer Center and New Orleans–based Ochsner Health recently announced a partnership to create Ochsner MD Anderson Cancer Center in southeastern Louisiana. Patients with cancer in the region now will have access to treatments that are among the most advanced in...
City of Hope Receives $32.3 Million From the California Institute for Regenerative Medicine to Advance Innovative Therapies
Researchers at City of Hope were awarded $32.3 million from the California Institute for Regenerative Medicine (CIRM) to support three novel phase I clinical trials evaluating innovative cell and gene therapies for patients with HIV, acute myeloid leukemia (AML), and severe aplastic anemia. Beckman ...
Catalyzing Change: Young Moroccan Oncologists Spearhead the Fight Against Sarcoma
The management of sarcoma presents several challenges because of its rarity and diverse subtypes, making accurate diagnosis and specialized treatment crucial. A multidisciplinary approach involving various experts from different cancer specialties is the optimal strategy to improve survival and...
Finding a New Life Purpose After Cancer
In the summer of 2012, I was living my dream. At 28 years old, I had gone from an impoverished childhood in South Central Los Angeles to the high life in the city of Los Angeles. Unable to afford to go to college, an after-school program helped launch me into a career in the hospitality industry. I ...
Surgical Oncologist Héber Salvador, MD, PhD, Offers an Inside Look at Cancer Care in Brazil, Complete With Its Diversity and Inequities
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, the Jerald L. & Carolynn J. Varner Professor of Surgical Oncology & Global Health at the University of Nebraska Medical Center, Omaha, spoke with Héber Salvador, MD, PhD,...
ACS Funds UAMS Study to Understand Treatment Resistance in Pancreatic Cancer
Adam Wolfe, MD, PhD, a radiation oncologist at the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute, has received a $583,200 grant from the American Cancer Society (ACS) to study radiation resistance in pancreatic cancer, a lethal disease with the highest...
From Texas to Sweden, Medical Oncologist Gil Morgan, MD, Enjoys Connecting the Cancer Community
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Gil Morgan, MD, a clinical oncologist formerly at the Division of Medical and Radiation Oncology at Skåne University Hospital, Lund, Sweden and now full-time Director of the OncoAlert...
Particulate Matter Concentrations and Incidence of Breast Cancer
Investigators have found that residing in areas with high levels of particulate air pollution may be associated with an increased risk of developing breast cancer, according to a recent study published by White et al in the Journal of the National Cancer Institute. Background Particulate matter...
SIO and ASCO Partner to Develop Integrative Oncology Care Recommendations for Anxiety and Depression in Patients With Cancer
The Society for Integrative Oncology (SIO) and ASCO have partnered to develop a new guideline on integrative oncology care of symptoms of anxiety and depression in adults with cancer. The guideline reviews the evidence for a range of integrative approaches, including mindfulness-based...
ASCO Participates in President’s Cancer Panel
ASCO joined the President’s Cancer Panel on September 7, 2023, to highlight the numerous ways ASCO is working to advance the National Cancer Plan and achieve President Biden’s Cancer Moonshot goal of “ending cancer as we know it.” This all-day, virtual event was the first public meeting in support...
ASCO Releases Rapid Recommendation Update on Use of Olanzapine to Treat Cancer-Related Cachexia
ASCO recently released a new rapid recommendation update that addresses the use of olanzapine to treat cancer-related cachexia, a topic originally addressed in its 2020 guideline on the management of cancer cachexia in adults with advanced cancer.1,2 At that time, there was insufficient evidence to ...
ASTRO Names FASTRO Recipients for 2023
A total of 29 distinguished members of the American Society for Radiation Oncology (ASTRO) have been named Fellows of ASTRO. The ASTRO Fellow designation, FASTRO, honors individuals who have contributed significantly to the Society through committee work, other volunteer service, and to the field...
New Assistant Program Director for Complex General Surgical Oncology Fellowship at Fox Chase Cancer Center
Andrea Porpiglia, MD, MSc, FACS, Associate Professor in the Department of Surgical Oncology at Fox Chase Cancer Center, has been promoted to Assistant Program Director for the Complex General Surgical Oncology Fellowship. “Dr. Porpiglia has been an instrumental part of teaching the next generation ...
More on Renal Cell Carcinoma From ASCO 2023: Focus on Atezolizumab Plus Cabozantinib vs Cabozantinib Alone
The addition of the monoclonal antibody atezolizumab to the tyrosine kinase inhibitor cabozantinib failed to improve progression-free survival and overall survival vs cabozantinib alone in patients with advanced renal cell carcinoma (previously treated with an immune checkpoint inhibitor) in the...
Highlights in Cancer and Aging From the 2023 ASCO Annual Meeting
The 2023 ASCO Annual Meeting again demonstrated the Society’s commitment to improving cancer care for all older adults. Pertinent questions related to treatment and management in this population were addressed in educational and oral abstract sessions, clinical science symposia, and case-based...
HERTHENA-Lung01: Patritumab Deruxtecan for Advanced EGFR-Mutant NSCLC
In the phase II HERTHENA-Lung01 trial reported in the Journal of Clinical Oncology, Helena Yu, MD, and colleagues found that patritumab deruxtecan (HER3-DXd), a new anti-HER3 antibody-drug conjugate, showed activity in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC)...
Understanding the Treatment of Waldenström’s Macroglobulinemia
Waldenström’s macroglobulinemia is a rare and incurable low-grade B-cell lymphoproliferative disease defined by specific genotypic subtypes that have implications for treatment response and long-term outcomes. Treatment—and there is no established standard—is mainly focused on controlling symptoms...
Distributing Scarce Cancer Drugs Legally and Ethically
During the COVID-19 pandemic, many medical specialties became familiar with supply chain interruptions resulting in drug, equipment, and personnel scarcity. Intensive care unit beds, staff, and essential medicines were at times in short supply. The federal government, individual states, and...
NeoCOAST: Durvalumab Monotherapy vs Combined With Other Immunotherapies for Early-Stage NSCLC
The anti–PD-L1 monoclonal antibody durvalumab in combination with other immuno-oncology agents may outperform treatment with durvalumab alone in the neoadjuvant setting for patients with early-stage non–small cell lung cancer (NSCLC), according to a recent study published by Cascone et al in Cancer ...
